Recombinant Rat MIP-3 alpha/CCL20 Protein, N- His & GST

MIP-3 alpha, also known as CCL20, is a chemokine that plays a crucial role in immune responses by attracting specific types of immune cells, notably CD4+ T lymphocytes and dendritic cells, to sites of inflammation. It is primarily produced by epithelial and endothelial cells in response to various stimuli, including infections and inflammatory cytokines. The significance of CCL20 in the pathogenesis of several diseases, particularly in autoimmune conditions, cancer, and chronic inflammatory disorders, has spurred considerable research interest. Understanding the mechanisms by which CCL20 mediates immune cell migration and its interactions with CCR6, its sole receptor, is vital for unraveling its role in both health and disease. To investigate these processes, researchers have developed recombinant CCL20 proteins, which facilitate the exploration of its biological functions, signaling pathways, and potential therapeutic applications. By utilizing recombinant technology, scientists aim to determine how CCL20 contributes to disease progression and assess its utility as a target for drug development, potentially leading to novel treatments for conditions characterized by dysregulated immune responses. The ongoing studies on MIP-3 alpha/CCL20 continue to enhance our understanding of immune system dynamics and open new avenues for intervention in disease management.